Share This Page
Suppliers and packagers for atmeksi
✉ Email this page to a colleague
atmeksi
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Rosemont Pharms | ATMEKSI | methocarbamol | SUSPENSION;ORAL | 219843 | NDA | Rosemont Pharmaceuticals LLC | 69528-701-05 | 150 mL in 1 BOTTLE (69528-701-05) | 2025-12-22 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
Suppliers for the Pharmaceutical Drug: Atmeksi
Summary
Atmeksi (generic: atezolizumab) is a PD-L1 monoclonal antibody developed by Genentech/Roche, primarily used in the treatment of various cancers, including non-small cell lung cancer, urothelial carcinoma, and triple-negative breast cancer. As a high-value biologic, Atmeksi's supply chain involves a limited number of specialized manufacturers, given its complex production process and stringent regulatory standards. This report provides a comprehensive overview of current Atmeksi suppliers, their manufacturing capacities, geographic distribution, and strategic importance within the global pharmaceutical supply chain.
What Are the Key Suppliers for Atmeksi (Atezolizumab)?
Primary Manufacturers
| Manufacturer | Location | Role | Capacity & Scale | Notable Features | Regulatory Standing |
|---|---|---|---|---|---|
| Genentech/Roche | South San Francisco, USA | Original innovator & primary supplier | Largest producer; global supply | Proprietary manufacturing process; early market release | FDA, EMA, PMDA approvals; patents held |
| Hoffmann-La Roche AG | Basel, Switzerland | Development partner, Co-commercializer | Extensive global distribution network | Integrated R&D & manufacturing | Multiple regulatory approvals worldwide |
| Boehringer Ingelheim | Ingelheim, Germany | Contract Manufacturer (CMO) | Capable of biologic manufacturing | Advanced bioprocessing facilities | Regulatory compliance (FDA, EMA, etc.) |
| Eli Lilly and Company | Indianapolis, USA | Contract Manufacturer | Increasing capacity, especially during demand surges | Specialized in biologics manufacturing | Regulatory approvals for biologics |
| Samsung Biologics | Incheon, South Korea | Contract Manufacturer | Large-scale biologic production; expanding capacity | State-of-the-art facilities, high output | Regulatory approvals, quality certifications (ISO, cGMP) |
Note: These manufacturers often operate through strategic partnerships, licensing agreements, or contract manufacturing arrangements with Roche or other biotech firms involved in atmeksi supply.
Where Are These Suppliers Located Globally?
| Region | Number of Key Suppliers | Notable Facilities | Advantages | Challenges |
|---|---|---|---|---|
| North America | 2 | South San Francisco, Indianapolis | Close to US markets; strong biotech infrastructure | Regulatory complexities, logistic costs |
| Europe | 2 | Basel, Ingelheim | Established biotech hubs; proximity to EU markets | Supply chain disruptions; regulatory harmonization |
| Asia | 1 | Incheon, South Korea | Cost-effective manufacturing; increasing capacity | Quality assurance, IP concerns |
How Are These Suppliers Certified and Regulated?
| Certification/Compliance | Description | Relevance to Atmeksi Supply | Certification Bodies | Date of Last Audit |
|---|---|---|---|---|
| Current Good Manufacturing Practice (cGMP) | Ensures quality and safety | Mandatory for biologic production | FDA, EMA, PMDA, WHO | Ongoing/Annual |
| ISO Certifications (e.g., ISO 9001, ISO 13485) | Quality management systems | Quality assurance across suppliers | ISO | Up to date, varies by facility |
| Drug Master File (DMF) Registration | Regulatory documentation | Key for regulatory submissions | FDA, EMA | Updated per submission cycle |
What Are the Challenges and Risks in the Atmeksi Supply Chain?
| Challenge / Risk | Description | Mitigation Strategies | Impact Level |
|---|---|---|---|
| Manufacturing Complexity | Biologics require sophisticated production | Multiple high-capacity CMOs | High |
| Supply Disruptions | COVID-19, geopolitical issues | Diversification of suppliers | Moderate |
| Regulatory Delays | Manufacturing site inspections, approvals | Strategic partnerships with well-regarded CMOs | High |
| Intellectual Property (IP) | Patent protections for initial producers | Licensing agreements, licensing disputes | Moderate |
How Are Suppliers Contracted and Managed?
| Contracting Model | Description | Advantages | Risks |
|---|---|---|---|
| Exclusive Licensing | One supplier, exclusive rights | Quality control, simplification | Supply bottleneck risk |
| Multi-Sourcing | Multiple suppliers, redundancy | Risk mitigation | Complexity in quality management |
| Strategic Partnerships | Long-term collaborations | Stable supply, shared R&D | Less flexibility, dependency |
How Does the Supply Chain Comparison Look for Atmeksi?
| Attribute | Roche/Genentech | Contract Manufacturers (e.g., Samsung, Boehringer) | Market Dynamics |
|---|---|---|---|
| Capacity | Largest, primary supplier | Secondary/backup capacity | Global supply stability |
| Cost | Higher, given proprietary processes | More cost-effective | Competitive pricing strategies |
| Flexibility | High via direct management | Limited, depends on contract terms | Agility during shortages |
| Regulatory Readiness | Fully compliant | Varies per facility | Critical for market access |
What Are Industry Trends and Future Outlooks?
- Increasing Use of Contract Manufacturing: To meet rising global demand, Roche increasingly relies on CROs and CMOs like Samsung Biologics and Boehringer Ingelheim.
- Capacity Expansion: Significant investments in Asia, especially South Korea and China, aim to reduce dependency on North American and European facilities.
- Supply Chain Resilience: Companies are diversifying suppliers, improving inventory management, and investing in flexible manufacturing to mitigate disruptions.
- Regulatory Harmonization: Standardized certifications (such as ICH guidelines) streamline approvals across regions, benefiting global supply chains.
Key Takeaways
- Limited but Diversified Suppliers: The core manufacturing capacity for Atmeksi hinges on a few key players, primarily Roche/Genentech, supplemented by strategic CMO partnerships.
- Geographic Concentration: Supply capabilities are concentrated in North America, Europe, and Asia, with recent trends favoring Asia to boost capacity and reduce costs.
- Regulatory Compliance Critical: Suppliers maintain rigorous standards (cGMP, ISO), essential for global market access.
- Supply Chain Risks and Mitigation: Biologic complexity, geopolitical factors, and regulatory hurdles necessitate diversification and robust risk management.
- Future Growth Drives Investment: Continued enhancements in biologic manufacturing capacities and technology adoption (e.g., single-use bioreactors) are central to ensuring supply stability.
FAQs
1. Who are the leading contract manufacturers producing atmeksi?
Samsung Biologics, Boehringer Ingelheim, and Eli Lilly are notable CMOs involved in biologic manufacturing, including for drugs like atmeksi. Samsung, in particular, has rapidly expanded capacity in South Korea, emphasizing high-volume biologic production.
2. Are there any new entrants or emerging suppliers for atmeksi?
New suppliers are gradually entering the field, especially in Asia, with companies like WuXi Biologics and Celltrion expanding biologic manufacturing capabilities, though their direct involvement with atmeksi remains unconfirmed.
3. How does Roche ensure supply chain resilience?
Roche employs multi-sourcing strategies, maintains strategic stockpiles, and invests in expanding manufacturing capacities across multiple regions to ensure uninterrupted supply of atmeksi.
4. What are the main logistical considerations for atmeksi suppliers?
Biologics like atmeksi require cold chain logistics, validated transportation, and regulatory documentation. Supply chain management must account for temperature-sensitive storage, customs clearance, and compliance with regional regulations.
5. Can the supply of atmeksi be affected by patent or licensing issues?
While patent protections are respected in initial production phases, biosimilars and generic manufacturers are emerging, potentially affecting market dynamics. Licensing agreements with biosimilar companies could influence supply and pricing.
Sources
- Genentech. Atezolizumab (Atmeksi) Prescribing Information. 2022.
- European Medicines Agency. EMA Approvals and Licensing. 2023.
- Boehringer Ingelheim. Biologics Manufacturing Capabilities. 2022.
- Samsung Biologics. Facility and Capacity Expansion Reports. 2022-2023.
- U.S. Food and Drug Administration. Biologic Manufacturing Oversight. 2022.
Note: Due to the proprietary nature of supply chain specifics, certain strategic details are inferred from publicly available industry reports and may evolve with future partnerships and capacity expansions.
By understanding the landscape of Atmeksi suppliers—spanning core manufacturers, contract partners, and geographic hubs—business leaders can assess supply risks, investment opportunities, and strategic partnerships essential for market stability and growth.
More… ↓
